S1931-Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial)
Posted Date: May 5, 2021
- Investigator: Shuchi Gulati
- Specialties: Cancer, Oncology
- Type of Study: Drug
The main objective of this study is to compare the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). The primary outcome measure is overall survival.
Participants Must Have A Histologically Proven Diagnosis Of Clear Cell Or Non-Clear Cell Renal Cell Carcinoma, Zubrod Performance Status Of 0-1, Treatment Naive Participants Must Have Scans Documenting Metastatic Disease Completed Within 90 Days Prior To Study Registration, Stable Disease. No Active Brain Metastases, No Kidney Transplant, No Other Malignancy Within 2 Years.
Kidney Cancer, Renal Cell Carcinoma
For More Information:
Uc Cancer Center